Pharma · Nasdaq · as of 2026-09-22 · mandate northvale_quality_v3 · outside book panel
Executive summary
Pharma · Nasdaq · as of 2026-09-22 · mandate northvale_quality_v3 · outside book panel
Executive summary
Business quality 80 · Valuation attractiveness 44 · merge rule_quality_pass_price_contested
Propose add ACME at committee-agreed size. Keep the valuation stretch explicit; do not scale the sleeve until Bull / Base assumptions are cited in the room.
phase3_initiation · MONITOR · page 2,841 · Q2 earnings call · 2026-08-12
“…Phase 3 cardiometabolic program… late-stage kickoff for the lead asset…”
Propose add · house book · target weight 1.50% · PROPOSAL_ONLY
Q. Does Phase 3 change the propose-add?
A. No. Flag is MONITOR only. Propose-add stands; sizing stays with IC.
PROPOSAL_ONLY · not a trade instruction · as_of 2026-09-22
Mandate northvale_quality_v3
as of 2026-09-22 · base → multiplier → target · house book
| Ticker | Base | × | Target | Action |
|---|---|---|---|---|
| ACME | — | 1.00 | 1.50% | Propose add |
| HLX | 2.40% | 1.00 | 2.40% | — |
| NVDX | 3.10% | 0.50 | 1.55% | Trim |
| ORBC | 1.80% | 1.00 | 1.80% | — |
| KLYN | 2.05% | 1.00 | 2.05% | — |
| VREX | 1.65% | 1.00 | 1.65% | — |
Single-name cap 3.0% · sector pharma sleeve within mandate band · no freeze on ACME or NVDX this as_of.
Capital moves only when humans approve · schedule is research classification only.
Same score spine as name dossiers · merge rule_quality_pass_price_contested on ACME · reconstructible from versioned run artifacts.
Templated book schedule · PROPOSAL_ONLY · not a trade instruction · as_of 2026-09-22 · mandate northvale_quality_v3